Understanding Verona Pharma Stocks – A Fundamental Analysis

By Ken Smith • Wednesday, May 21 10:00 • Permanent Link

Mid-cap Health Care company Verona Pharma has moved 0.0% so far today on a volume of 54,396, compared to its average of 1,445,090. In contrast, the S&P 500 index moved -0.0%.

Verona Pharma trades -20.56% away from its average analyst target price of $94.1 per share. The 10 analysts following the stock have set target prices ranging from $76.0 to $107.0, and on average have given Verona Pharma a rating of buy.

If you are considering an investment in VRNA, you'll want to know the following:

Verona Pharma has moved 493.1% over the last year, and the S&P 500 logged a change of 11.9%
Based on its trailing earnings per share of -2.0, Verona Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -37.4 while the S&P 500 average is 29.3
VRNA has a forward P/E ratio of -267.0 based on its forward 12 month price to earnings (EPS) of $-0.28 per share
Its Price to Book (P/B) ratio is 30.07 compared to its sector average of 3.19
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
Based in London, the company has 209 full time employees and a market cap of $6.35 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.